IMI vs 23andMe Which Is Stronger?

IMI and 23andMe are two companies in the rapidly growing biotech sector, each with their own unique strengths and opportunities. IMI, a leading provider of medical imaging solutions, has shown steady growth and profitability over the years. On the other hand, 23andMe, a direct-to-consumer genetic testing company, has attracted significant attention for its innovative approach to personal health and ancestry exploration. Investors looking to capitalize on the expanding healthcare industry may find opportunities in both IMI and 23andMe stocks.

IMI or 23andMe?

When comparing IMI and 23andMe, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between IMI and 23andMe.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. IMI has a dividend yield of 1.66%, while 23andMe has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. IMI reports a 5-year dividend growth of -7.81% year and a payout ratio of 29.10%. On the other hand, 23andMe reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with IMI P/E ratio at 18.17 and 23andMe's P/E ratio at -3.62. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. IMI P/B ratio is 4.21 while 23andMe's P/B ratio is 15.93.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, IMI has seen a 5-year revenue growth of 0.20%, while 23andMe's is -0.57%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with IMI's ROE at 23.85% and 23andMe's ROE at -189.28%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are £1753.00 for IMI and $4.33 for 23andMe. Over the past year, IMI's prices ranged from £1512.00 to £1911.00, with a yearly change of 26.39%. 23andMe's prices fluctuated between $4.33 and $20.40, with a yearly change of 371.13%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.